Avanafil for the Treatment of men With Erectile Dysfunction: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Jinze Li, MM1,*, Lei Peng, MM1,*, Dehong Cao, MD2,3,*, Lujia He, MD4, Yunxiang Li, MD1, and Qiang Wei, MD2

Abstract
Previous studies have reported the clinical efficacy of avanafil for erectile dysfunction (ED), but these findings are controversial. This study aims to investigate the safety and efficacy of avanafil for ED. EMBASE, PubMed, and Cochrane Library were searched extensively to obtain eligible studies. Clinical outcomes including successful vaginal penetration (SVP), successful intercourse (SI), International Index of Erectile Function-Erectile Function domain (IIEF-EF) score and treatment adverse events (TAEs) were compared using RevMan v.5.3. Eight RCTs involving 3,709 patients were included. The analysis demonstrated that compared with placebo, the SVP (RR = 3.20, 95% CI [2.60, 3.95], p < .001), SI (RR = 2.53, 95% CI [2.19, 2.92], p < .001), change in IIEF-EF score (MD = 4.57, 95% CI [3.68, 5.46], p < .0001) and TAEs (RR = 1.78, 95% CI [1.38, 2.31], p < .0001) were significantly higher in the avanafil. In addition, avanafil 200 mg were higher than avanafil 100 mg in SI (RR = 0.86, 95% CI [0.75, 0.99], p = .03) and change in IIEF-EF score (MD = −1.34, 95% CI [−1.67, −1.01], p < .001), but there were no obvious differences in SVP (RR = 0.89; 95% CI [0.74, 1.08], p = .23) and TAEs (RR = 0.97, 95% CI [0.83, 1.14], p = .74) between the two doses. The present evidence suggests that avanafil (especially 200 mg) has the potential to be the drug of choice for ED, but more strict and larger sample size RCTs are need to validate the findings.

Keywords
Erectile dysfunction, avanafil, meta-analysis, randomized controlled trial

Received May 16, 2019; revised September 4, 2019; accepted September 16, 2019

Erectile dysfunction (ED) is defined as the inability of men to obtain or maintain enough erection to complete a satisfactory sexual activity (Hatzimouratidis et al., 2010). As a public health issue, ED has caused a serious negative psychological impact on patients and may affect the quality of life and the marital relationship of patients. The prevalence of ED increases with age, and it is necessary to find an effective and safe way to treat male ED (Laumann et al., 2005).

Oral phosphodiesterase type 5 inhibitors (PDE5-Is) are considered to be an effective method for the treatment of ED. Three of these drugs (such as sildenafil, vardenafil, and tadalfil) are recommended by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the treatment of ED (Bruziches, Francomano, Gareri, Lenz, & Aversa, 2013; Smith et al., 2013). In the
past 10 years, due to the occasional failure and adverse events, many patients are not satisfied with those drugs. As a new generation of PDE5-Is, avanafil is gradually accepted by patients due to its high selectivity and low adverse event response rate (Burke & Evans, 2012).

Although Wang performed a meta-analysis of the effectiveness of avanafil in the treatment of ED, the results are still controversial (Wang et al., 2014). The study was designed to include more relevant randomized controlled trials (RCTs) and analyze more parameters (such as the International Index of Erectile Function-Erectile Function domain [IIEF-EF] score) to assess the safety and efficacy of avanafil for the treatment of ED and provide updated clinical evidence.

**Methods**

**Search Strategy**

This study was conducted under the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement.

As of April 2019, EMBASE, PubMed, and Cochrane Library were searched by the computer to distinguish all RCTs about the treatment of ED with avanafil. The search language was limited to English, and the following search terms were used: “avanafil,” “erectile dysfunction,” “randomized controlled trial.” Besides, the author manually searched and applied Google scholarly literature to avoid the omission of studies.

**Inclusion/Exclusion Criteria**

If all correlative RCTs suffice the following criteria, they were included in the analysis: (a) all the studies on the therapy of ED with avanafil; (b) all patients were 18 years or older, and were clinically diagnosed with ED; (c) the control group in this study was either a placebo or a different dose of avanafil; (d) this study provided at least one indicator of outcomes that can be analyzed. On the contrary, studies were excluded if (a) the research data were based on the results of animal experiments; (b) the study data could not be obtained; or (c) all studies in non-RCTs. Figure 1 presents a flow chart of the study selection process.
After examining the title, abstract, and full text, two authors selected the literature in strict accordance with the inclusion criteria and then extracted the data according to the predesigned table for cross-checking. Differences can be dealt with by discussion. Data including first author, year of publication, type of study design, interventions, total number and age of subjects, characteristics of the patient populations, and outcome indicators were extracted. Data were collected independently by two investigators, and the missing data were acquired by contacting the author. The following outcomes data were extracted: successful vaginal penetration (SVP), successful intercourse (SI), change in IIEF-EF score, and treatment adverse events (TAEs). When continuous variables appeared in the studies in the form of the median (range), the mean values (standard deviation) was calculated by us (Luo, Wan, Liu, & Tong, 2018).

Data Extraction

According to the new five-level evidence grading standard established by the Oxford Center for Evidence-Based Medicine (OCEBM), the level of evidence for all RCTs was 2b (Table 1). The quality assessment was based on methodological quality assessment criteria recommended by the Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (Higgins et al., 2011). Where “high risk” stands for the high risk of bias, “low risk” stands for the low risk of bias and “unclear risk” stands for the absence of adequate information in the research to conduct the bias evaluation (Figure 2). All differences were resolved through discussions between the two commentators.

The funnel plot contributed a qualitative appraisal of the bias of published studies, and no evidence of bias was observed (Figure 3).

Table 1. Basic Information and Characteristics of Studies for Meta-Analysis.

| Study             | Country | Designs | LOE | Invention | Patients (n) | Age (years) | Dot (weeks) | Characteristics of the patient populations |
|-------------------|---------|---------|-----|-----------|--------------|-------------|-------------|-------------------------------------------|
| Jung et al. (2010)| Korea   | RCT     | 2b  | A 100, 200 mg vs PL | 8, 8 vs 6 | 24.0 ± 1.7, 23.0 ± 1.3 vs 23.0 ± 1.6 | 2           | ≥18–45 years, weighing >45 kg and within ±20% of ideal body weight |
| Goldstein et al. (2012) | America | RCT     | 2b  | A 100, 200 mg vs PL | 157, 156 vs 155 | 56.4, 56.1 vs 55.8 | 12          | ≥18 years, type 1 or 2 diabetes, a ≥6-mo history of mild to severe ED |
| Goldstein et al. (2012) | America | RCT     | 2b  | A 100, 200 mg vs PL | 129, 131 vs 130 | 58.2 ± 9.6, 57.5 ± 9.0 vs 58.2 ± 8.6 | 12          | ≥18 years, a ≥6-mo history of mild to severe ED |
| Zhao et al. (2012) | Korea   | RCT     | 2b  | A 100, 200 mg vs PL | 68, 66 vs 66 | 55.8 ± 8.2, 56.6 ± 8.3 vs 54.9 ± 8.9 | 12          | >20 years, a ≥6-mo history of ED |
| Mulhall et al. (2013) | America | RCT     | 2b  | A 100, 200 mg vs PL | 99, 99 vs 100 | 58.9 ± 5.9, 57.7 ± 6.6 vs 58.6 ± 5.9 | 12          | 18–70 years, a ≥6-mo history of ED after radical prostatectomy |
| Belkoff, Tursi, Uy, Smith, and Jones (2015) | America | RCT     | 2b  | A 100, 200 mg vs PL | 147, 147 vs 146 | ≥18, ≥18 vs ≥18 | 8           | ≥18 years, a ≥6-mo history of ED after radical prostatectomy |
| Hellstrom et al. (2015) | America | RCT     | 2b  | A 100, 200 mg vs PL | 147, 200 vs 145 | 58.5 ± 10.2, 57.9 ± 10.6 vs 58.3 ± 9.9 | 8           | ≥18 years, a ≥6-mo history of ED |
| Park et al. (2017) | Korea   | RCT     | 2b  | A 100, 200 mg vs PL | 40, 39 vs 39 | 57.2 ± 8.0, 56.1 ± 6.7 vs 56.7 ± 9.0 | 8           | 19–70 years, a ≥6-mo history of ED |

Note. RCT = randomized controlled trial; LOE = level of evidence; A = avanafil; PL = placebo; vs = versus; Dot = duration of treatment; ED = erectile dysfunction; mo = month.
Statistical Analysis

The RevMan 5.3 and Stata 14.0 were applied for data analysis. Mean difference (MD) and risk ratio (RR) were used as the effect indexes for continuous and dichotomous data respectively, and $p$ value and 95% confidence interval (CI) were given for both. Heterogeneity between studies was judged by Cochran’s $Q$ and $I^2$ statistics. When there was statistical homogeneity between studies ($p > .1$, $I^2 < 50%$), a fixed-effects model was chosen for meta-analysis. Otherwise, a random-effects model was utilized. About all statistical consequences, $p < .05$ was regarded as statistically significant.

Results

Study Characteristics

A total of 426 related literature were obtained by a preliminary examination. Three hundred and ninety
duplicate and unrelated studies were removed, and 36 studies were selected. After further reading the full text, eight RCTs (Belkoff, Tursi, Uy, Smith, & Jones, 2015; Goldstein, Jones, et al., 2012; Goldstein, McCullough, et al., 2012; Hellstrom et al., 2015; Mulhall et al., 2013; Park et al., 2017; Zhao et al., 2012) involving 2,398 patients were included in the meta-analysis (Figure 1). In addition, the sample size was estimated according to the methodology introduced in the study (Belkoff et al., 2015), and some data were obtained from the Cochrane Central Register of Controlled Trials (Goldstein, Jones, et al., 2012; Goldstein, McCullough, et al., 2012; Mulhall et al., 2013). The basic information and baseline characteristics of the incorporated studies are reported in Table 1, and the methodological quality evaluation of RCTs is presented in Figure 3.

Successful Vaginal Penetration

In the included studies, the data of SVP were reported in six RCTs involving 1,865 patients (Goldstein, Jones, et al., 2012; Goldstein, McCullough, et al., 2012; Mulhall et al., 2013; Park et al., 2017; Zhao et al., 2012). The combined results displayed a significant improvement in SVP of patients in the avanafil group compared with the placebo group (RR = 3.20, 95% CI [2.60, 3.95], p < .001). In the study, a subgroup analysis of patients treated with 100 mg and 200 mg of avanafil for ED was performed. The pooled analysis demonstrated that compared to the placebo group, the 100 mg group had obvious statistical significance (RR = 3.02, 95% CI [2.24, 4.07], p < .001), and similar results were identified in the 200 mg group (RR = 3.39, 95% CI [2.60, 3.95], p < .001; Figure 4A).

Successful Intercourse

The SI data were extracted from seven RCTs (Belkoff et al., 2015; Goldstein, Jones, et al., 2012; Goldstein, McCullough, et al., 2012; Hellstrom et al., 2015; Mulhall et al., 2013; Park et al., 2017; Zhao et al., 2012). The comprehensive analysis demonstrated that the proportion of SI in the avanafil group was significantly greater than that in the placebo group (RR = 2.53, 95% CI [2.19, 2.92], p < .001). The subgroup analysis results showed that both the avanafil 100 mg and 200 mg groups had significantly higher SI ratios than the placebo group (100 mg: RR = 2.36, 95% CI [1.93, 2.90], p < .001; 200 mg: RR = 2.70, 95% CI [2.21, 3.30], p < .001; Figure 4B).

IIEF-EF Score

Five RCTs recorded the change in IIEF-EF score data (Goldstein, Jones, et al., 2012; Goldstein, McCullough, et al., 2012; Hellstrom et al., 2015; Mulhall et al., 2013; Park et al., 2017). Results indicated that the change in the IIEF-EF score of the avanafil group was significantly higher than that of the placebo group (MD = 4.57, 95% CI [3.68, 5.46], p < .001). In addition, similar results were found in the subgroup analysis. The MD was 3.88 (95% CI [2.69, 5.07], p < .001) for avanafil 100 mg group and 5.26 (95% CI [3.68, 5.46], p < .001) for avanafil 200 mg group (Figure 5A).

Treatment Adverse Events

In the final statistical analysis, seven RCTs reported the TAEs (Goldstein, Jones, et al., 2012; Goldstein, McCullough, et al., 2012; Hellstrom et al., 2015; Jung et al., 2010; Mulhall et al., 2013; Park et al., 2017; Zhao et al., 2012). The number of TAEs increased significantly in the avanafil group compared with the placebo group (RR = 1.78, 95% CI [1.38, 2.31], p < .0001; Figure 5B). The subgroup analysis suggested that the number of TAEs increased significantly in the 100 mg group compared with the placebo group (RR = 1.79, 95% CI [1.22, 2.62], p = .003). The same results were observed in the 200 mg group (RR = 1.81, 95% CI [1.22, 2.69], p = .003).

Avanafil 100 mg Versus Avanafil 200 mg

This analysis evaluated whether there were differences in efficacy and safety for ED treatment using either 100 mg or 200 mg avanafil (Figure 6). The pooled analysis revealed that avanafil 200 mg were higher than avanafil 100 mg in SI (RR = 0.86, 95% CI [0.75, 0.99], p = .03) and change in IIEF-EF score (MD = −1.34, 95% CI [−1.67, −1.01], p < .001), but there were no differences in SVP (RR = 0.89; 95% CI [0.74, 1.08], p = .27) and
TAEs (RR = 0.97, 95% CI [0.83, 1.14], p = .74) between the two doses.

**Sensitivity Analysis**

Sensitivity analysis was performed to determine the impact of each study data on the final outcomes. There were no significant differences in overall pooled RRs and MDs, regardless of which study was deleted (Figure 7).

**Discussion**

Although ED is a benign disease, it affects the patient’s body and mental health and is closely related to the patient’s quality of life, sexual relationship, and family stability (Laumann et al., 2005). The treatment of ED can only improve the degree of an erection and alleviate the pain of patients, but it cannot be completely cured. Avanafil is a new type of PDE5-Is. Compared with others, it has good pharmacodynamic and pharmacokinetic
effects and has high selectivity for PDE5 isozyme, so there are fewer adverse reactions (Burke & Evans, 2012).

The present study showed that improvement of SVP in ED patients with avanafil at different doses (100 mg and 200 mg) was better than that in placebo patients, which was consistent with the analysis results of Wang et al. (2014) and Corona, Rastrelli, Burri, Jannini, and Maggi (2016). PDE5 is the major reactive enzyme for cGMP catabolism in cells and mediates the signal of erection disappearance. And the PDE5-Is (especially avanafil) are analogs of the cGMP structure, they competitively bind to the catalytic group of PDE5 and inhibit the hydrolysis of cGMP, contributing to the increase of cGMP level, thereby increasing penile blood flow and amplifying the neural signal of erection (Andersson, 2003; Dean & Lue, 2005). It suggested that oral avanafil was an effective method for the treatment of ED. In addition, both Goldstein, McCullough, et al. (2012) and our study proved that there was no statistically significant difference in SVP between avanafil at 100 mg and 200 mg.

**Figure 5.** Forest plot for the comparison of the avanafil (100 mg and 200 mg subgroup) and placebo group (A: IIEF-EF score; B: TAEs). IIEF-EF = International Index of Erectile Function-Erectile Function domain; TAEs = treatment adverse events.
Consequently, it is debatable whether high doses of avanafil have an advantage in improving SVP in ED patients. This statistical analysis demonstrated that compared with placebo, avanafil (100 mg and 200 mg) significantly increased the proportion of SI in ED patients. A higher proportion of SI in patients receiving 200 mg of avanafil than in the lower-dose (100 mg) group. A previous meta-analysis incorporating four RCTs concluded that there was no difference in SI between the avanafil 100 mg and 200 mg groups (Cui, Li, Zong, Yan, & Zhang, 2014). There are a variety of reasons for this difference, for example, the study population’s region, race, number, and age. Data from an epidemiological survey in China identified that higher prevalence of ED was observed in adult men with severe smoking, diabetes, and benign prostatic hyperplasia (Zhang, Yang, Li, & Li, 2017), and a recent study suggested that diabetic men with depressive symptoms may have a higher risk of developing ED (Wang, Yang, Cai, Wang, & Weng, 2018). These studies suggested that the treatment of ED patients may be affected by a combination of factors. The study conclusions are reasonable and warrant further objective evaluation of the impact of avanafil on improving SI at different doses (100 mg and 200 mg).
Since its introduction in 1997 (Rosen et al., 1997), the International Index of Erectile Function score (IIEF) has been widely accepted for its sensitivity and specificity in detecting changes in the treatment of ED patients. Hence, the IIEF-EF score has become one of the principal methods to estimate the quality of male ED. Our meta-analysis of change in IIEF-EF score demonstrated that different doses (100 mg or 200 mg) of avanafil were better than the placebo, which was consistent with the results of previous clinical trials, the total TAEs of avanafil were acceptable. In a 12-week phase III clinical study (Goldstein, McCullough, et al., 2012), the overall TAE rates for the avanafil 100 mg group, avanafil 200 mg group, and the placebo group were 42.9%, 38.9%, and 26.1%, respectively. The overall incidence of TAEs in patients receiving avanafil and placebo was 32.4% (423/1036) and 18.9% (246/1302), respectively. Further, the overall occurrence of TAEs was 18.2% (253/1389) and 22.5% (269/1197) in patients taking 100 mg and 200 mg avanafil, respectively. The most frequently reported adverse events included headache, flushing, nasal congestion, nasopharyngitis, and back pain (Belkoff et al., 2013; Goldstein, McCullough, et al., 2012; Hellstrom et al., 2012). It is gratifying to note that the extent of adverse events is relatively mild, patients can tolerate them, and there are few reports of serious complications in all studies.

Swearingen and his colleagues reported that compared with sildenafil, sublingual nitroglycerin had a lesser effect on blood pressure and heart rate after oral administration of avanafil for 1 h \((p < .05)\); the adverse events associated with a clinically significant reduction in systolic blood pressure \((≥30 \text{ mmHg})\) induced by avanafil were less common than sildenafil \((15\% \text{ vs } 29\%, \ p < .05; \text{Swearingen, Nehra, Morelos, & Peterson, 2013})\). Another study also reported that avanafil is 120-fold and 10,000-fold more selective for PDE5 than PDE6 and PDE1, while vardenafil is 21-fold and 1,000-fold and sildenafil is 16-fold and 380-fold (Kedia, Uckert, Assadi-Pour, Kuczyk, & Albrecht, 2013). There is a reason to believe that avanafil is a wise choice for patients who cannot tolerate TAEs to sildenafil and vardenafil.

Since its introduction in 1997 (Rosen et al., 1997), the International Index of Erectile Function score (IIEF) has been widely accepted for its sensitivity and specificity in detecting changes in the treatment of ED patients. Hence, the IIEF-EF score has become one of the principal methods to estimate the quality of male ED. Our meta-analysis of change in IIEF-EF score demonstrated that different doses (100 mg or 200 mg) of avanafil were better than the placebo, which was consistent with the results of previous RCTs. Also, subgroup analyses indicated that higher doses (200 mg) of avanafil significantly increased change in IIEF-EF score in ED patients compared with avanafil 100 mg. There is no suspicion that avanafil can increase the IIEF-EF score significantly in patients with ED, and 200 mg of avanafil is better than 100 mg.

This meta-analysis showed a higher incidence of total TAEs in avanafil compared with placebo, and no difference was identified between avanafil 200 mg and 100 mg. According to the results of previous clinical trials, the total TAEs of avanafil were acceptable. In a 12-week phase III clinical study (Goldstein, McCullough, et al., 2012), the overall TAE rates for the avanafil 100 mg group, avanafil 200 mg group, and the placebo group were 42.9%, 38.9%, and 26.1%, respectively. The overall incidence of TAEs in patients receiving avanafil and placebo was 32.4% (423/1036) and 18.9% (246/1302), respectively. Further, the overall occurrence of TAEs was 18.2% (253/1389) and 22.5% (269/1197) in patients taking 100 mg and 200 mg avanafil, respectively. The most frequently reported adverse events included headache, flushing, nasal congestion, nasopharyngitis, and back pain (Belkoff et al., 2013; Goldstein, McCullough, et al., 2012; Hellstrom et al., 2012). It is gratifying to note that the extent of adverse events is relatively mild, patients can tolerate them, and there are few reports of serious complications in all studies.

Swearingen and his colleagues reported that compared with sildenafil, sublingual nitroglycerin had a lesser effect on blood pressure and heart rate after oral administration of avanafil for 1 h \((p < .05)\); the adverse events associated with a clinically significant reduction in systolic blood pressure \((≥30 \text{ mmHg})\) induced by avanafil were less common than sildenafil \((15\% \text{ vs } 29\%, \ p < .05; \text{Swearingen, Nehra, Morelos, & Peterson, 2013})\). Another study also reported that avanafil is 120-fold and 10,000-fold more selective for PDE5 than PDE6 and PDE1, while vardenafil is 21-fold and 1,000-fold and sildenafil is 16-fold and 380-fold (Kedia, Uckert, Assadi-Pour, Kuczyk, & Albrecht, 2013). There is a reason to believe that avanafil is a wise choice for patients who cannot tolerate TAEs to sildenafil and vardenafil.

Figure 7. Sensitivity analysis. (A: sensitivity analysis of SVP; B: sensitivity analysis of SI; C: sensitivity analysis of IIEF-EF score; D: sensitivity analysis of TAEs). SVP = successful vaginal penetration; SI = successful intercourse; IIEF-EF = International Index of Erectile Function-Erectile Function domain; TAEs = treatment adverse events.

Since its introduction in 1997 (Rosen et al., 1997), the International Index of Erectile Function score (IIEF) has been widely accepted for its sensitivity and specificity in detecting changes in the treatment of ED patients. Hence, the IIEF-EF score has become one of the principal methods to estimate the quality of male ED. Our meta-analysis of change in IIEF-EF score demonstrated that different doses (100 mg or 200 mg) of avanafil were better than the placebo, which was consistent with the results of previous RCTs. Also, subgroup analyses indicated that higher doses (200 mg) of avanafil significantly increased change in IIEF-EF score in ED patients compared with avanafil 100 mg. There is no suspicion that avanafil can increase the IIEF-EF score significantly in patients with ED, and 200 mg of avanafil is better than 100 mg.

This meta-analysis showed a higher incidence of total TAEs in avanafil compared with placebo, and no difference was identified between avanafil 200 mg and 100 mg. According to the results of previous clinical trials, the total TAEs of avanafil were acceptable. In a 12-week phase III clinical study (Goldstein, McCullough, et al., 2012), the overall TAE rates for the avanafil 100 mg group, avanafil 200 mg group, and the placebo group were 42.9%, 38.9%, and 26.1%, respectively. The overall incidence of TAEs in patients receiving avanafil and placebo was 32.4% (423/1036) and 18.9% (246/1302), respectively. Further, the overall occurrence of TAEs was 18.2% (253/1389) and 22.5% (269/1197) in patients taking 100 mg and 200 mg avanafil, respectively. The most frequently reported adverse events included headache, flushing, nasal congestion, nasopharyngitis, and back pain (Belkoff et al., 2013; Goldstein, McCullough, et al., 2012; Hellstrom et al., 2012). It is gratifying to note that the extent of adverse events is relatively mild, patients can tolerate them, and there are few reports of serious complications in all studies.

Swearingen and his colleagues reported that compared with sildenafil, sublingual nitroglycerin had a lesser effect on blood pressure and heart rate after oral administration of avanafil for 1 h \((p < .05)\); the adverse events associated with a clinically significant reduction in systolic blood pressure \((≥30 \text{ mmHg})\) induced by avanafil were less common than sildenafil \((15\% \text{ vs } 29\%, \ p < .05; \text{Swearingen, Nehra, Morelos, & Peterson, 2013})\). Another study also reported that avanafil is 120-fold and 10,000-fold more selective for PDE5 than PDE6 and PDE1, while vardenafil is 21-fold and 1,000-fold and sildenafil is 16-fold and 380-fold (Kedia, Uckert, Assadi-Pour, Kuczyk, & Albrecht, 2013). There is a reason to believe that avanafil is a wise choice for patients who cannot tolerate TAEs to sildenafil and vardenafil.

There are certain limitations in the present analysis: (a) part of the study has a small sample size; (b) because the etiology of ED in some studies differs in the severity of ED and the expected response to the drug, the potential heterogeneity of the subjects used in the meta-analysis may be greater; (c) the follow-up period in the eight studies was shorter. Besides, most of the RCTs included did not explicitly describe allocation concealment.

Conclusion

The current evidence suggests that the SVP, SI, and IIEF-EF score in men who received avanafil improved significantly. Although some TAEs exist, they are within the tolerable range of patients. In summary, avanafil (especially 200 mg) has the potential to be the drug of
choice for the treatment of ED, but more strict and larger sample size RCTs are needed to verify the findings of this meta-analysis.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Yunxiang Li https://orcid.org/0000-0002-4019-7843

**References**

Andersson, K. E. (2003). Erectile physiological and pathophysiological pathways involved in erectile dysfunction. *The Journal of Urology, 170*(2 Pt 2), S6–S13; discussion S13–14. doi:10.1097/01.ju.0000075362.08363.a4

Belkoff, L. H., McCullough, A., Goldstein, I., Jones, L., Bowden, C. H., DiDonato, K., . . . Day, W. W. (2013). An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. *International Journal of Clinical Practice, 67*(4), 333–341. doi:10.1111/iipc.12065

Belkoff, L. H., Tursi, J. P., Uy, J., Smith, T. M., & Jones, L. A. (2015). PD45-12 Avanafil efficacy within 15 minutes of dosing in men with mild to severe erectile dysfunction by demographic and baseline clinical characteristics. *The Journal of Urology, 193*(4s), e906. doi:10.1016/j.juro.2015.02.2584

Bruziches, R., Francomano, D., Gareri, P., Lenzi, A., & Aversa, A. (2013). An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. *Expert Opinion on Pharmacotherapy, 14*(10), 1333–1344. doi:10.1517/14656566.2013.799665

Burke, R. M., & Evans, J. D. (2012). Avanafil for treatment of erectile dysfunction: Review of its potential. *Vascular Health and Risk Management, 2012*(8), 517–523. doi:10.2147/vhrm.S26712

Corona, G., Rastrelli, G., Burri, A., Jannini, E. A., & Maggi, M. (2016). The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: Comprehensive review and meta-analysis. *Expert Opinion on Drug Safety, 15*(2), 237–247. doi:10.1517/14644102.2016.1130126

Cui, Y. S., Li, N., Zong, H. T., Yan, H. L., & Zhang, Y. (2014). Avanafil for male erectile dysfunction: A systematic review and meta-analysis. *Asian Journal of Andrology, 16*(3), 472–477. doi:10.4103/1008-682X.123670

Dean, R. C., & Lue, T. F. (2005). Physiology of penile erection and pathophysiology of erectile dysfunction. *Urologic Clinics of North America, 32*(4), 379–395. doi:10.1016/j.ucl.2005.08.007

Goldstein, I., Jones, L. A., Belkoff, L. H., Karlin, G. S., Bowden, C. H., Peterson, C. A., . . . Day, W. W. (2012). Avanafil for the treatment of erectile dysfunction: A multicenter, randomized, double-blind study in men with diabetes mellitus. *Mayo Clinic Proceedings, 87*(9), 843–852. doi:10.1016/j.mayocp.2012.06.016

Goldstein, I., McCullough, A. R., Jones, L. A., Hellstrom, W. J., Bowden, C. H., Didonato, K., . . . Day, W. W. (2012). A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. *The Journal of Sexual Medicine, 9*(4), 1122–1133. doi:10.1111/j.1743-6109.2011.02629.x

Hatzimouratidis, K., Amar, E., Eardley, I., Giuliano, F., Hatzichristou, D., Montorsi, F., . . . Wespes, E. (2010). Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. *European Urology, 57*(5), 804–814. doi:10.1016/j.euro.2010.02.020

Hellstrom, W. J., Freier, M. T., Serefoglu, E. C., Lewis, R. W., DiDonato, K., & Peterson, C. A. (2012). A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction. *BJU International, 111*(1), 137–147. doi:10.1111/j.1464-410X.2012.11267.x

Hellstrom, W. J., Kaminetsky, J., Belkoff, L. H., Goldstein, L., Tursi, J. P., Uy, J., . . . Day, W. W. (2015). Efficacy of avanfil 15 minutes after dosing in men with erectile dysfunction: A randomized, double-blind, placebo controlled study. *The Journal of Urology, 194*(2), 485–492. doi:10.1016/j.juro.2014.12.101

Higgins, J. P., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., . . . Sterne, J. A. (2011). The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ, 343*, d5928. doi:10.1136/bmj.d5928

Jung, J., Choi, S., Cho, S. H., Ghim, J. L., Hwang, A., Kim, U., . . . Lim, H. S. (2010). Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: A single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. *Clinical Therapeutics, 32*(6), 1178–1187. doi:10.1016/j.clinthera.2010.06.011

Kedia, G. T., Uckert, S., Assadi-Pour, F., Kuczyk, M. A., & Albrecht, K. (2013). Avanafil for the treatment of erectile dysfunction: Initial data and clinical key properties. *Therapeutic Advances in Urology, 5*(1), 35–41. doi:10.1177/1756287212466282

Laumann, E. O., Nicolosi, A., Glasser, D. B., Paik, A., Gingell, C., Moreira, E., & Wang, T. (2005). Sexual problems among women and men aged 40–80 y: Prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. *International Journal of Impotence Research, 17*(1), 39–57. doi:10.1038/sj.ijir.3901250

Luo, D., Wan, X., Liu, J., & Tong, T. (2018). Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Statistical Methods in Medical Research, 27*(6), 1785–1805. doi:10.1177/0962280216669183

Mulhall, J. P., Burnett, A. L., Wang, R., McVary, K. T., Moul, J. W., Bowden, C. H., . . . Day, W. W. (2013). A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. *The Journal of Urology, 189*(6), 2229–2236. doi:10.1016/j.juro.2012.11.177
Park, H. J., Kim, S. W., Kim, J. J., Lee, S. W., Paick, J. S., Ahn, T. Y., . . . Park, N. C. (2017). A randomized, placebo-controlled, double-blind, multi-center therapeutic confirmatory study to evaluate the safety and efficacy of avanafil in Korean patients with erectile dysfunction. *Journal of Korean Medical Science, 32*(6), 1016–1023. doi:10.3346/jkms.2017.32.6.1016

Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997). The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. *Urology, 49*(6), 822–830.

Smith, W. B., II, McCaslin, I. R., Gokce, A., Mandava, S. H., Trost, L., & Hellstrom, W. J. (2013). PDE5 inhibitors: Considerations for preference and long-term adherence. *International Journal of Clinical Practice, 67*(8), 768–780. doi:10.1111/ijcp.12074

Swearingen, D., Nehra, A., Morelos, S., & Peterson, C. A. (2013). Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. *Drugs in Context, 2013*, 212248. doi:10.7573/dic.212248

Wang, H., Yuan, J., Hu, X., Tao, K., Liu, J., & Hu, D. (2014). The effectiveness and safety of avanafil for erectile dysfunction: A systematic review and meta-analysis. *Current Medical Research and Opinion, 30*(8), 1565–1571. doi:10.1185/03007995.2014.909391

Wang, X., Yang, X., Cai, Y., Wang, S., & Weng, W. (2018). High prevalence of erectile dysfunction in diabetic men with depressive symptoms: A meta-analysis. *The Journal of Sexual Medicine, 15*(7), 935–941. doi:10.1016/j.jsxm.2018.05.007

Zhao, C., Kim, S. W., Yang, D. Y., Kim, J. J., Park, N. C., Lee, S. W., . . . Park, J. K. (2012). Efficacy and safety of avanafil for treating erectile dysfunction: Results of a multicentre, randomized, double-blind, placebo-controlled trial. *BJU International, 110*(11), 1801–1806. doi:10.1111/j.1464-410X.2012.11095.x